55- Minutolo R, Borrelli S, Chiodini P, Scigliano R, Trucillo P, Baldanza D, et al. Changing the
timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week
uncontrolled trial. Am J Kidney Dis. 2007;50(6):908–17. - Rahman M, Greene T, Phillips RA, Agodoa LY, Bakris GL, Charleston J, et al. A trial of 2
strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Hypertension. 2013;61(1):82–8. - Hermida RC, Ayala DE, Mojon A, Fernandez JR. Bedtime dosing of antihypertensive medi-
cations reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22(12):2313–21. - Calhoun DA, Jones D, Textor S, et al.; American Heart Association Professional Education
Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific state-
ment from the American Heart Association Professional Education Committee of the Council
for High Blood Pressure Research. Circulation. 2008;117:510–526. - Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment.
J Am Coll Cardiol. 2008;52:1749–57. - Persell SD. Prevalence of resistant hypertension in the United States, 2003–08. Hypertension.
2011;57:1076–80. - Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis.
Circulation. 2012;125(13):1594–6. - Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hyperten-
sion in the United States, 1988-2000. JAMA. 2003;290:199–206. - ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The
Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial. Major out-
comes in high-risk hypertensive patients randomized to angiotensin-converting enzyme
inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–97. - Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension its identification and epidemi-
ology. Nat Rev Nephrol. 2012;9(1):51–8. - Moser M, Setaro JF. Clinical practice. Resistant or difficult to control hypertension. N Engl
J Med. 2006;355:385–92. - Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, et al. Patterns
of persistence with antihypertensive medications in newly diagnosed hypertensive patients in
Italy: a retrospective cohort study in primary care. J Hypertens. 2005;23:2093–100. - Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihyper-
tensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ.
2008;336:1114–7. - Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, Miller CD, Ziemer
DC, Barnes CS. Clinical inertia. Ann Intern Med. 2001;135:825–34. - Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz
MA. Inadequate management of blood pressure in a hypertensive population. N Engl J Med.
1998;339:1957–63. - James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al.
2014 evidence-based guideline for the management of high blood pressure in adults: report
from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA.
2014;311(5):507–20. - ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 practice guidelines
for the management of arterial hypertension of the European Society of Hypertension (ESH)
and the European Society of Cardiology (ESC): ESH/ESC task force for the Management of
Arterial Hypertension. J Hypertens. 2013;31(10):1925–38. - De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, et al. Prognosis of
CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol.
2011;6(10):2421–8. - De Nicola L, Borrelli S, Chiodini P, Zamboli P, Iodice C, Gabbai FB, et al. Hypertension
management in chronic kidney disease: translating guidelines into daily practice. J Nephrol.
2011;24(6):733–41.
4 The Importance of Ambulatory and Home Monitoring Blood Pressure in Resistant...